Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia
Phase II, Randomized, Double-blind, Multi-centered Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia (HGPIN) or Atypical Small Acinar Proliferation (ASAP)
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia
Phase II, Randomized, Double-blind, Multi-centered Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia (HGPIN) or Atypical Small Acinar Proliferation (ASAP)
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia
Phase II, Randomized, Double-blind, Multi-centered Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia (HGPIN) or Atypical Small Acinar Proliferation (ASAP)
Status: Enrolling
Updated:  12/31/1969
James A Haley VA
mi
from
Tampa, FL
Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia
Phase II, Randomized, Double-blind, Multi-centered Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia (HGPIN) or Atypical Small Acinar Proliferation (ASAP)
Status: Enrolling
Updated: 12/31/1969
James A Haley VA
mi
from
Tampa, FL
Click here to add this to my saved trials
Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases
Phase II Trial of Zemplar (19-nor-1 a,25-Dihydroxyvitamin D2, Paricalcitol Capsule) on Bony Remodeling in Advanced Androgen-Insensitive Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases
Phase II Trial of Zemplar (19-nor-1 a,25-Dihydroxyvitamin D2, Paricalcitol Capsule) on Bony Remodeling in Advanced Androgen-Insensitive Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Satraplatin and Prednisone to Treat Prostate Cancer
A Phase II Study of Satraplatin and Prednisone in Metastatic Androgen Independent Prostate Cancer (AIPC)
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Satraplatin and Prednisone to Treat Prostate Cancer
A Phase II Study of Satraplatin and Prednisone in Metastatic Androgen Independent Prostate Cancer (AIPC)
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Satraplatin and Prednisone to Treat Prostate Cancer
A Phase II Study of Satraplatin and Prednisone in Metastatic Androgen Independent Prostate Cancer (AIPC)
Status: Enrolling
Updated:  12/31/1969
Associates in Oncology and Hematology
mi
from
Rockville, MD
Satraplatin and Prednisone to Treat Prostate Cancer
A Phase II Study of Satraplatin and Prednisone in Metastatic Androgen Independent Prostate Cancer (AIPC)
Status: Enrolling
Updated: 12/31/1969
Associates in Oncology and Hematology
mi
from
Rockville, MD
Click here to add this to my saved trials
Contrast Enhanced Transrectal Ultrasonography (TRUS) to Assess Prostatic Vascularity After Radiotherapy (XRT)
Contrast Enhanced Transrectal Ultrasound (TRUS) to Assess Prostatic Vascularity as a Measure of Treatment Response and Early Prediction of Treatment Failure After XRT
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Contrast Enhanced Transrectal Ultrasonography (TRUS) to Assess Prostatic Vascularity After Radiotherapy (XRT)
Contrast Enhanced Transrectal Ultrasound (TRUS) to Assess Prostatic Vascularity as a Measure of Treatment Response and Early Prediction of Treatment Failure After XRT
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer
Randomized, Controlled Phase II Study of Valproic Acid in Patients With Non-metastatic Biochemical Progression of Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer
Randomized, Controlled Phase II Study of Valproic Acid in Patients With Non-metastatic Biochemical Progression of Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Green Tea, Black Tea, or Water in Treating Patients With Prostate Cancer Undergoing Surgery
Effects of Brewed Green and Black Tea on Inflammation, Apoptosis and Oxidation in Men With Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Green Tea, Black Tea, or Water in Treating Patients With Prostate Cancer Undergoing Surgery
Effects of Brewed Green and Black Tea on Inflammation, Apoptosis and Oxidation in Men With Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Green Tea, Black Tea, or Water in Treating Patients With Prostate Cancer Undergoing Surgery
Effects of Brewed Green and Black Tea on Inflammation, Apoptosis and Oxidation in Men With Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Veterans Affairs Medical Center - West Los Angeles
mi
from
Los Angeles, CA
Green Tea, Black Tea, or Water in Treating Patients With Prostate Cancer Undergoing Surgery
Effects of Brewed Green and Black Tea on Inflammation, Apoptosis and Oxidation in Men With Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Veterans Affairs Medical Center - West Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Proton Therapy for Low and Intermediate Risk Prostate Cancer
A Phase II Study of Hypofractionated Image Guided Proton Radiation Therapy for Low and Intermediate Risk Adenocarcinoma of the Prostate
Status: Enrolling
Updated:  12/31/1969
University of Florida Proton Therapy Institute
mi
from
Jacksonville, FL
Proton Therapy for Low and Intermediate Risk Prostate Cancer
A Phase II Study of Hypofractionated Image Guided Proton Radiation Therapy for Low and Intermediate Risk Adenocarcinoma of the Prostate
Status: Enrolling
Updated: 12/31/1969
University of Florida Proton Therapy Institute
mi
from
Jacksonville, FL
Click here to add this to my saved trials
PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment
Pilot Immunotherapy Study of Combination PSMA and TARP Peptide With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment
Pilot Immunotherapy Study of Combination PSMA and TARP Peptide With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment
Pilot Immunotherapy Study of Combination PSMA and TARP Peptide With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment
Status: Enrolling
Updated:  12/31/1969
Ponce School of Medicine
mi
from
Ponce,
PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment
Pilot Immunotherapy Study of Combination PSMA and TARP Peptide With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment
Status: Enrolling
Updated: 12/31/1969
Ponce School of Medicine
mi
from
Ponce,
Click here to add this to my saved trials
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
Yale University School of Medicine
mi
from
New Haven, CT
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
Carolina BioOncology Institute
mi
from
Huntersville, NC
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
Carolina BioOncology Institute
mi
from
Huntersville, NC
Click here to add this to my saved trials
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
The Christ Hospital
mi
from
Cincinnati, OH
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
The Christ Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
Pinnacle Oncology Hematology
mi
from
Scottsdale, AZ
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
Pinnacle Oncology Hematology
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
University of Michigan Cancer Center
mi
from
Ann Arbor, MI
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
University of Michigan Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Research Institute
mi
from
Nashville, TN
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated:  12/31/1969
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated: 12/31/1969
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer
A Study to Assess if a Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer
Status: Enrolling
Updated:  12/31/1969
SUNY Downstate Medical Center (DMC)
mi
from
Brooklyn, NY
Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer
A Study to Assess if a Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer
Status: Enrolling
Updated: 12/31/1969
SUNY Downstate Medical Center (DMC)
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer
A Study to Assess if a Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer
Status: Enrolling
Updated:  12/31/1969
Kings County Hopsital Center
mi
from
Brooklyn, NY
Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer
A Study to Assess if a Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer
Status: Enrolling
Updated: 12/31/1969
Kings County Hopsital Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer
A Study to Assess if a Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer
Status: Enrolling
Updated:  12/31/1969
Weill Medical College of Cornell University
mi
from
New York, NY
Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer
A Study to Assess if a Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer
Status: Enrolling
Updated: 12/31/1969
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Study of Focal Cryoablation in Low-Risk Prostate Cancer
A Phase II Study of Focal Cryoablation in Low-Risk Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Study of Focal Cryoablation in Low-Risk Prostate Cancer
A Phase II Study of Focal Cryoablation in Low-Risk Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy
A Phase Ib Trial of Mushroom Powder in Biochemically Recurrent Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
City of Hope Medical Center
mi
from
Duarte, CA
White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy
A Phase Ib Trial of Mushroom Powder in Biochemically Recurrent Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy
A Phase Ib Trial of Mushroom Powder in Biochemically Recurrent Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
South Pasadena Cancer Center
mi
from
South Pasadena, CA
White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy
A Phase Ib Trial of Mushroom Powder in Biochemically Recurrent Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
South Pasadena Cancer Center
mi
from
South Pasadena, CA
Click here to add this to my saved trials
Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy
Phase I Trial of In Situ Gene Therapy for Locally Recurrent Prostate Cancer Following Radiation Therapy Failure Using Sodium/Iodide Symporter and Radioiodine
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy
Phase I Trial of In Situ Gene Therapy for Locally Recurrent Prostate Cancer Following Radiation Therapy Failure Using Sodium/Iodide Symporter and Radioiodine
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
C-11 Choline PET-CT Scan in Finding Metastases in Patients With Newly Diagnosed High-Risk Prostate Cancer
A Pilot Study of Use of 11C-Choline PET-CT in the Metastatic Evaluation of Patients With Newly Diagnosed High Risk Adenocarcinoma of the Prostate
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
C-11 Choline PET-CT Scan in Finding Metastases in Patients With Newly Diagnosed High-Risk Prostate Cancer
A Pilot Study of Use of 11C-Choline PET-CT in the Metastatic Evaluation of Patients With Newly Diagnosed High Risk Adenocarcinoma of the Prostate
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Telephone Counseling: Men With Prostate Cancer & Partners
Telephone Counseling With Men With Prostate Cancer and Partners
Status: Enrolling
Updated:  12/31/1969
University of Arizona
mi
from
Tucson, AZ
Telephone Counseling: Men With Prostate Cancer & Partners
Telephone Counseling With Men With Prostate Cancer and Partners
Status: Enrolling
Updated: 12/31/1969
University of Arizona
mi
from
Tucson, AZ
Click here to add this to my saved trials
Characterization of Prostate Cancer With 3T MR
Characterization of Prostate Cancer With 3T MR
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Characterization of Prostate Cancer With 3T MR
Characterization of Prostate Cancer With 3T MR
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer
A Pilot Randomized Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer
A Pilot Randomized Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer
A Phase I, Non-randomized, Multiple Dose, Dose Escalation Study of the Safety, PK, PD and Efficacy of Therapeutic Vaccine, BP-GMAX-CD1, Plus Activating Agent, AP1903, in Patients With Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center Houston, CRU
mi
from
Houston, TX
MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer
A Phase I, Non-randomized, Multiple Dose, Dose Escalation Study of the Safety, PK, PD and Efficacy of Therapeutic Vaccine, BP-GMAX-CD1, Plus Activating Agent, AP1903, in Patients With Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center Houston, CRU
mi
from
Houston, TX
Click here to add this to my saved trials
Aberrant Gene Expression Prostate Carcinoma
Identification of Aberant Gene Expression in Human Prostatic Carcinoma
Status: Enrolling
Updated:  12/31/1969
Lahey Clinic
mi
from
Burlington, MA
Aberrant Gene Expression Prostate Carcinoma
Identification of Aberant Gene Expression in Human Prostatic Carcinoma
Status: Enrolling
Updated: 12/31/1969
Lahey Clinic
mi
from
Burlington, MA
Click here to add this to my saved trials
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Status: Enrolling
Updated:  12/31/1969
Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
mi
from
Fairbanks, AK
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Status: Enrolling
Updated: 12/31/1969
Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
mi
from
Fairbanks, AK
Click here to add this to my saved trials
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Status: Enrolling
Updated:  12/31/1969
East Bay Radiation Oncology Center
mi
from
Castro Valley, CA
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Status: Enrolling
Updated: 12/31/1969
East Bay Radiation Oncology Center
mi
from
Castro Valley, CA
Click here to add this to my saved trials
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Status: Enrolling
Updated:  12/31/1969
Valley Medical Oncology Consultants - Castro Valley
mi
from
Castro Valley, CA
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Status: Enrolling
Updated: 12/31/1969
Valley Medical Oncology Consultants - Castro Valley
mi
from
Castro Valley, CA
Click here to add this to my saved trials
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Status: Enrolling
Updated:  12/31/1969
North Bay Cancer Center
mi
from
Fairfield, CA
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Status: Enrolling
Updated: 12/31/1969
North Bay Cancer Center
mi
from
Fairfield, CA
Click here to add this to my saved trials
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Status: Enrolling
Updated:  12/31/1969
Valley Medical Oncology
mi
from
Fremont, CA
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Status: Enrolling
Updated: 12/31/1969
Valley Medical Oncology
mi
from
Fremont, CA
Click here to add this to my saved trials
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Status: Enrolling
Updated:  12/31/1969
Contra Costa Regional Medical Center
mi
from
Martinez, CA
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Status: Enrolling
Updated: 12/31/1969
Contra Costa Regional Medical Center
mi
from
Martinez, CA
Click here to add this to my saved trials
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Medical Center
mi
from
Modesto, CA
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Medical Center
mi
from
Modesto, CA
Click here to add this to my saved trials
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Status: Enrolling
Updated:  12/31/1969
El Camino Hospital Cancer Center
mi
from
Mountain View, CA
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Status: Enrolling
Updated: 12/31/1969
El Camino Hospital Cancer Center
mi
from
Mountain View, CA
Click here to add this to my saved trials
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Status: Enrolling
Updated:  12/31/1969
Alta Bates Summit Medical Center - Summit Campus
mi
from
Oakland, CA
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Status: Enrolling
Updated: 12/31/1969
Alta Bates Summit Medical Center - Summit Campus
mi
from
Oakland, CA
Click here to add this to my saved trials
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Status: Enrolling
Updated:  12/31/1969
Tom K Lee, Incorporated
mi
from
Oakland, CA
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Status: Enrolling
Updated: 12/31/1969
Tom K Lee, Incorporated
mi
from
Oakland, CA
Click here to add this to my saved trials
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Status: Enrolling
Updated:  12/31/1969
CCOP - Bay Area Tumor Institute
mi
from
Oakland, CA
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Status: Enrolling
Updated: 12/31/1969
CCOP - Bay Area Tumor Institute
mi
from
Oakland, CA
Click here to add this to my saved trials